Live Chat ×
Skip to main content

Management of Chronic Lymphocytic Leukemia: Use of Novel Therapies in Treatment while Remediating Adverse Events


A Series of Live Webinars Approved for CME

TO REGISTER:
Click here to complete your registration.


DATES AND TIMES
Friday, January 15, 2021
8:00 – 9:00 AM ET (7:00 - 8:00 AM CT / 5:00 - 6:00 AM PT)

Friday, January 22, 2021
12:00 – 1:00 PM ET (11:00 AM - 12:00 PM CT / 9:00 - 10:00 AM PT)

Tuesday, February 9, 2021
12:00 – 1:00 PM ET (11:00 AM - 12:00 PM CT / 9:00 - 10:00 AM PT)

Wednesday, February 10, 2021
8:00 – 9:00 AM ET (7:00 - 8:00 AM CT / 5:00 - 6:00 AM PT)

Thursday, February 11, 2021
8:00 – 9:00 AM ET (7:00 - 8:00 AM CT / 5:00 - 6:00 AM PT)

Friday, February 12, 2021
12:00 – 1:00 PM ET (11:00 AM - 12:00 PM CT / 9:00 - 10:00 AM PT)

Wednesday, March 10, 2021
12:30 – 1:30 PM ET (11:30 AM - 12:30 PM CT / 9:30 - 10:30 AM PT)

AGENDA
Welcome and Introductions
Current Guidelines and Emerging Data for Targeted Therapies for CLL
Alleviation of Side Effects Associated with Targeted Therapies for CLL
Conclusions
Questions and Answers

PROGRAM DESCRIPTION
Targeted therapy has increased the treatment options for chronic lymphocytic leukemia (CLL) and survival rates have improved in patients with advanced disease. However, the majority of patients still develop relapsed or refractory disease due to treatment-induced or naturally occurring tumor-cell subsets that are treatment resistant. The high likelihood of disease recurrence necessitates greater optimization of treatment planning, in order to improve the time to disease response, and, ultimately, to enhance patient survival.

This activity, “Management of Chronic Lymphocytic Leukemia: Use of Novel Therapies in Treatment while Remediating Adverse Events,” will review current guidelines for advanced CLL, including targeted therapy recommendations with small-molecule inhibitors and therapeutic monoclonal antibodies. The education will assess current data to determine which agents should be used in specific patient subpopulations, as well as those with or without comorbidities.

STEERING COMMITTEE
Paul M. Barr, MD
Medical Director, Clinical Trial Office
Associate Professor of Medicine
James P. Wilmot Cancer Institute
University of Rochester Medical Center
Rochester, NY

Paul M. Barr, MD is an Associate Professor of Medicine and the Medical Director of the Clinical Trials Office (CTO) at the James P. Wilmot Cancer Institute at the University of Rochester Medical Center. His internal medicine and hematology oncology training were completed at Case Western Reserve University; the latter supported by a National Institutes of Health (NIH)/National Cancer Institute (NCI) K12 award. Additional clinical research training was achieved through the American Society of Hematology Clinical Research Training Institute.

Dr. Barr’s research is focused on the development of novel treatment combinations for lymphoma and chronic lymphocytic leukemia. He has led several single institution, multi-center and cooperative group studies. His early research was supported by pilot grants from the Wilmot Fellowship and the Rochester NIH Specialized Program of Research Excellence Award in Lymphoma, as well as a career development grant awarded by the Lymphoma Research Foundation. Ongoing research includes: 1) defining treatment for early progressing follicular lymphoma through the National Clinical Trials Network supported SWOG 1608 trial; 2) incorporating PI3K inhibition into the treatment armamentarium through an investigator-initiated multicenter study of umbralisib, ublituximab, and venetoclax; and 3) further defining the role of first-line BTK inhibition in CLL through a single-center investigator-initiated study of an acalabrutinib-based combination.

Dr. Barr’s focus on clinical-trial design and an administrative position as the CTO Director is supported by an NCI National Clinical Trials Network Lead Academic Participating Site Award, for which he serves as Principal Investigator (PI). He also serves as University of Rochester PI for the SWOG oncology cooperative group and sits on the SWOG Board of Governors. He remains active in the Association of American Cancer Institutes, Clinical Research Initiative, having previously served on the group’s steering committee.

Ryan W. Jacobs, MD
Principal Investigator, Lymphoma Section
Levine Cancer Institute
Atrium Health
Charlotte, NC


Ryan W. Jacobs, MD
joined the Levine Cancer Institute (LCI) in Charlotte, NC in 2015 and has served as a clinician and Principal Investigator in the Lymphoma Section since that time. His clinical practice is comprised of patients with diagnoses of Hodgkin’s and non-Hodgkin’s lymphoma. Dr. Jacobs has both a clinical and research focus on patients with chronic lymphocytic leukemia (CLL). In his role as a Principal Investigator, he oversees the clinical trials conducted at LCI that involve the treatment of patients with CLL. As the CLL expert for the LCI/Atrium Health system, he is responsible for creating and overseeing the patient care pathways involving the treatment of CLL patients in a network that spans North and South Carolina.

In addition to clinical trials, Dr. Jacobs has a research interest in real-world outcomes of patients with CLL on novel therapies and has contributed to this field of research by evaluating patients across North and South Carolina treated in a variety of clinical settings. Dr. Jacobs graduated from Baylor College of Medicine in Houston, TX in 2009. He then completed his internship and residency in internal medicine at Vanderbilt University in Nashville, TN in 2012. Dr. Jacobs returned to Houston and completed his training with his hematology/oncology fellowship at MD Anderson Cancer Center in 2015. Dr. Jacobs is board-certified in hematology, medical oncology, and internal medicine. Through LCI’s adjunct affiliation, Dr. Jacobs is an Assistant Professor of Medicine at the University of North Carolina, Chapel Hill.

TARGET AUDIENCE
This activity is intended for community-based medical oncologists and other clinicians involved in the care of patients with CLL.

LEARNING OBJECTIVES
This program is designed to address ACGME and NAM competencies, including delivering patient-centered care and practicing evidence-based medicine.

At the conclusion of this activity, participants should be able to:

  • Evaluate the updated clinical guidelines for targeted therapies in the treatment of CLL patients
  • Integrate clinical data regarding the use of novel targeted agents to treat CLL in the appropriate patient subpopulations
  • Remediate toxicities associated with targeted therapies to improve patient outcomes
  • Apply methods to encourage shared decision-making between the multidisciplinary cancer care team and the patient
ACCREDITATION
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of USF Health and Rockpointe. USF Health is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION
USF Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For information about the accreditation of this program, please email: CPDsupport@usf.edu.

POTENTIAL CONFLICTS OF INTEREST
USF Health endorses the standards of the ACCME that require everyone in a position to control the content of an accredited educational activity to disclose all financial relationships with commercial interests that are related to the content of the educational activity. All accredited activities must be balanced, independent of commercial bias, and promote improvements or quality in healthcare. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

A conflict of interest is created when individuals in a position to control the content of an accredited educational activity have a relevant financial relationship with a commercial interest which therefore may bias his/her opinion and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.

USF Health will identify, review, and resolve all conflicts of interest that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation, but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

FACULTY DISCLOSURES
The faculty and steering committee reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Paul M. Barr, MD: Consultant: AbbVie, AstraZeneca, Celgene, Genentech, Gilead, Janssen, Merck, MorphoSys, Pharmacyclics, Seattle Genetics, TG Therapeutics, Verastem; Grants/Research Support: AstraZeneca, TG Therapeutics

Ryan W. Jacobs, MD: Advisory Board: AstraZeneca, Pharmacyclics, Seattle Genetics, Verastem; Consultant: AbbVie, Verastem; Grants/Research Support: Pharmacyclics, TG Therapeutics; Speaker's Bureau: AbbVie, AstraZeneca, Genentech, Janssen, Pharmacyclics, Sanofi Genzyme 

NON-FACULTY CONTENT CONTRIBUTORS
Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Chad Williamson, MS, MBA, CMPP; Blair St. Amand; USF Health CPD Staff: Nothing to disclose

DISCLAIMER
The information provided at this CME/CE activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

EOA/ADA
USF is an Equal Opportunity/ Affirmative Action/ Equal Access Institution.

NON-ENDORSEMENT
USF Health does not endorse any product, material, or service mentioned in association with this activity.

FDA DISCLOSURE
The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of a
pproved uses.

SYSTEM CHECK
To ensure your computer is compatible for the live event, please perform a system check by clicking on the link http://livewebcast.net/test or by typing it into your internet browser. Please perform the system check on the same computer you will use for the live event. If your computer is compatible, you will receive a confirmation message on your screen and hear audio. Otherwise, please contact the Help Desk at (888) 364-8804 to resolve any issues.

INSTRUCTIONS FOR PARTICIPANTS AND OBTAINING CME CREDIT
There is no fee for this activity. To receive credit, participants must register, view the live CME/CE activity in its entirety, complete the post-test, with a score of 75% or better, and the evaluation. The estimated time for completion of this activity is 1 hour. To receive a certific
ate, participants must demonstrate mastery of the presented material via the post-test. Participants are allowed to take the post-test twice.

If you will be watching the webinar in a group setting, please note all group participants will need to register individually in order to complete the post-test and evaluation to receive credit.

Jointly provided by USF Health and Rockpointe
  

This program is supported by an educational grant from AstraZeneca, and a co-supported educational grant from Pharmacyclics, LLC, an AbbVie Company, and Janssen Biotech Inc., administered by Janssen Scientific Affairs, LLC.